On November 8, 2018 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that Scott Wolchko, President and Chief Executive Officer, will present at two upcoming investor conferences in November (Press release, Fate Therapeutics, NOV 8, 2018, View Source [SID1234531048]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2018 London Healthcare Conference at 4:40 p.m. UTC on Thursday, November 15, 2018 in London.
Piper Jaffray 30th Annual Healthcare Conference at 12:30 p.m. ET on Tuesday, November 27, 2018 in New York City.
Live webcasts of the presentations will be available through the investor relations section of the Company’s website at www.fatetherapeutics.com. Following the live webcasts, an archived replay will be available on the Company’s website.